Ozempic / Semaglutide Insurance Coverage & Off-Label Obesity Denial Class Action
Case Overview
This class action targets two of the nation's largest health insurers for alleged bad-faith and systematic denial of coverage for GLP-1 receptor agonist medications — chiefly semaglutide (brand names Ozempic and Wegovy) — prescribed for obesity (BMI ≥ 30) and obesity-related conditions. Plaintiffs allege that Cigna and Elevance maintained blanket "weight-loss drug" exclusions in employer-sponsored health plans and applied automated prior-authorization denial scripts that failed to consider individual medical necessity, in violation of ERISA plan terms, state insurance regulations, and the Mental Health Parity and Addiction Equity Act's analog obesity provisions. Insurers allegedly continued denials even after the American Medical Association recognized obesity as a chronic disease and after Wegovy received FDA approval specifically for cardiovascular risk reduction in 2024.
The lawsuit seeks to certify a nationwide class of insured patients who were denied coverage for GLP-1 medications for obesity between 2021 and the present. Plaintiffs demand reimbursement of out-of-pocket drug costs — which can exceed $1,000 per month without insurance — as well as statutory penalties, attorney fees, and injunctive relief compelling individualized medical necessity reviews for GLP-1 prescriptions. The case is one of several parallel actions challenging insurer GLP-1 denial practices filed in federal courts in 2024 and 2025, reflecting a broader national litigation trend as demand for weight-loss drugs surges.
Who May Qualify
U.S. residents enrolled in a Cigna or Elevance Health (Anthem) insurance plan who were denied coverage or reimbursement for a GLP-1 medication (such as Ozempic, Wegovy, Rybelsus, or Mounjaro) prescribed for obesity or an obesity-related condition between January 2021 and the present, and who paid out of pocket or went without the medication as a result.
Frequently Asked Questions
Can I sue my insurance company for denying Ozempic or Wegovy coverage?
You may have a claim if your Cigna or Anthem/Elevance plan denied coverage for a GLP-1 medication prescribed for obesity and the denial was based on a blanket exclusion rather than an individual medical-necessity review. This lawsuit is actively seeking class members who paid out of pocket or went without the drug.
Why are insurers allowed to deny Ozempic coverage?
Many employer health plans include broad exclusions for "weight-loss" drugs. Plaintiffs argue these blanket exclusions are illegal under ERISA and state law when a medication is prescribed for a recognized chronic disease (obesity) or an FDA-approved indication like cardiovascular risk reduction.
Has the Ozempic insurance denial lawsuit settled?
No. As of mid-2025 the case is in early litigation in the Eastern District of Pennsylvania. No settlement has been announced, and the parties are briefing threshold issues including class certification.